Company / Cost of Revenue
NOVAVAX INC Cost of Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$73.0M
FY2025
5-year range
$0 / $343.8M
FY2021-FY2025
Trend
-64.0%
vs FY2024
Sector context
#49 of 85
Health Care
What the data says
At $73M, NOVAVAX INC's cost of revenue ranks #37 of 85 in the Health Care sector. Improved from $344M to $73M over the past 2 years.
Based on SEC 10-K filings.
$73M in FY2025.
Improved from $344M to $73M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#37 of 85 in Health CareTop 42% of 85This company $73.0M Sector average $2.0B
▼
-96.3% below sector average
Key checks
Key Insights
- In FY2025, cost of revenue decreased 64.0% year-over-year.
- Ranks #49 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.0M | -64.0% |
| FY2024 | $202.7M | -41.0% |
| FY2023 | $343.8M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026